dc.contributor.author |
Mitchell, N.J. |
|
dc.contributor.author |
Kumi, J. |
|
dc.contributor.author |
Johnson, N.M. |
|
dc.contributor.author |
Dotse, E. |
|
dc.contributor.author |
Marroquin-Cardona, A. |
|
dc.contributor.author |
Wang, J.S. |
|
dc.contributor.author |
Jolly, P.E. |
|
dc.contributor.author |
Ankrah, N.-A. |
|
dc.contributor.author |
Phillips, T.D. |
|
dc.date.accessioned |
2018-12-11T15:08:59Z |
|
dc.date.available |
2018-12-11T15:08:59Z |
|
dc.date.issued |
2013-05 |
|
dc.identifier.other |
https://doi.org/10.3109/1354750X.2013.798031 |
|
dc.identifier.other |
Volume 18, Issue 5, Pages 391-398 |
|
dc.identifier.uri |
http://ugspace.ug.edu.gh/handle/123456789/26332 |
|
dc.description.abstract |
Aflatoxin B1 is a persistent public health issue in Ghana. Assessment of AFB1 intervention efficacy is currently dependent on long-term biomarkers. This study was designed to determine whether daily AFM1 biomarker levels could be utilized as an early detection method for intervention efficacy. Participants were treated with a refined calcium montmorillonite clay (UPSN) or a placebo (calcium carbonate) in a crossover study. Urine samples were assessed for AFM1 levels daily. UPSN treatment reduced AFM1 biomarkers by 55% compared to the placebo. This is the first study to show that daily urinary AFM1 levels can be used as a biomarker of internal aflatoxin B1 exposure in short-term intervention trials to determine efficacy. © 2013 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Biomarkers |
en_US |
dc.subject |
Aflatoxin |
en_US |
dc.subject |
Enterosorption therapy |
en_US |
dc.subject |
Ghana |
en_US |
dc.subject |
Liver cancer |
en_US |
dc.title |
Reduction in the urinary aflatoxin M1 biomarker as an early indicator of the efficacy of dietary interventions to reduce exposure to aflatoxins |
en_US |
dc.type |
Article |
en_US |